Resilience

Resilience is engaged in the manufacturing of cell and gene therapies, vaccines, biologics, and nucleic acids. Resilience partners with other firms in order to help them develop and scale their products.

NewsHeat chart

  • Week
  • Month
  • Year
  • Media news
  • Corp news
Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

  • Valuation
  • Share Price
  • Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round
Funding Amount
Post-Money Valuation
Share Price
Series D11 Aug, 2023
***
***
***
Private Equity10 Jan, 2023
***
***
***
Series D6 Jun, 2022
***
***
***
Series C1 Aug, 2021
***
***
***
Series B23 Nov, 2020
***
***
***
Series A1 Jan, 2020
***
***
***

*** - To view the data, please log into your account or create a new one.

News related to Resilience1

Filter by
Sort by
Resilience
Mar 28, 2023 •Show on chart

As US plots biomanufacturing boost, National Resilience nets $410M loan from Defense Department

Resilience will channel the cash toward its goal of building biomanufacturing capacity and capabilities on U.S. soil ...

https://www.fiercepharma.com/manufacturing/white-house-eyes-biomanufacturing-boost-local-producer-national-resilience-adds-410m

Investors6

Lux CapitalLux Capital
GVGV
8VC8VC
New Enterprise AssociatesNew Enterprise Associates
ARCH Venture PartnersARCH Venture Partners
Mubadala Investment CompanyMubadala Investment Company

Resilience Twitter